Skip to content

The Intelligent Prevention And Control System And Strategy For The Whole Disease Cycle Of Diabetic Nephropathy

The Intelligent Prevention And Control System And Strategy For The Whole Disease Cycle Of Diabetic Nephropathy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06843304
Enrollment
2000
Registered
2025-02-24
Start date
2024-01-01
Completion date
2027-12-31
Last updated
2025-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy, T2DM

Brief summary

Diabetic nephropathy is one of the most severe microvascular complications of diabetes and a major cause of premature death and disability. It has become a leading cause of end-stage renal failure both in China and worldwide, consuming substantial medical resources. The establishment of a comprehensive regulatory system for the development and progression of diabetic nephropathy is a critical need for effective prevention and control. However, there is a lack of representative cohorts covering the entire disease cycle of diabetic nephropathy both domestically and internationally, creating technical bottlenecks in comprehensively describing its developmental patterns. This project aims to expand and integrate existing large-sample natural population cohorts and prospective follow-up cohorts covering the entire disease cycle of diabetes and diabetic nephropathy. It will construct a panoramic life database to identify risk factors, clinical phenotypes, and multimodal biomarkers at different disease stages. By integrating multi-organ interactions (e.g., kidney, eye), the project will establish novel imaging and functional assessment technologies for microvascular complications. Utilizing artificial intelligence to process multimodal medical data, it will build and validate risk prediction models and evaluation systems for the entire disease cycle of diabetic nephropathy. The project will develop effective intelligent prevention and treatment strategies for diabetic nephropathy, promote the adoption of new technologies, and establish a medical quality control system to provide services for medical institutions. Ultimately, it aims to improve and sustain medical quality, reducing the incidence of end-stage renal disease.

Interventions

None listed

Sponsors

Chinese PLA General Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

T2DM Inclusion Criteria: * Age ≥18 years old, gender is not limited * Diagnosed with type 2 diabetes * A history of type 2 diabetes for more than 5 years * Negative proteinuria * Creatinine is normal * Good compliance, voluntarily sign informed consent

Exclusion criteria

* Incomplete medical records * Lack of fundus microvascular examination or new imaging technology examination results data * Combined with autoimmune diseases and tumors Type 2 diabetes patients undergoing renal biopsy Inclusion Criteria: * Age ≥18 years old, gender is not limited * Diagnosed with type 2 diabetes * Kidney damage (microalbuminuria or dominant albuminuria or renal insufficiency) * Have undergone renal puncture biopsy and have complete renal pathological diagnosis data * Sign informed consent voluntarily

Design outcomes

Primary

MeasureTime frameDescription
The incidence of complex renal endpoints3 yearsThe incidence of complex renal endpoints includes eGFR decreased progressively by more than 30% from baseline, ESRD and all-cause death.

Countries

China

Contacts

Primary ContactZheyi Dong, MD
shengdai26@163.com+86 13810261592

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026